Research programme: dual E-selectin inhibitors/CXCR4 receptor antagonists - GlycoMimetics
Alternative Names: Anti-Leukemia Drug – GlycoMimetics; GMI-1257Latest Information Update: 24 Feb 2023
At a glance
- Originator GlycoMimetics
- Class Small molecules
- Mechanism of Action CXCR4 receptor antagonists; E-selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Acute myeloid leukaemia in USA (PO) (GlycoMimetics pipeline, February 2023)
- 22 Feb 2023 Discontinued - Preclinical for Solid tumours in USA (PO) (GlycoMimetics pipeline, February 2023)
- 28 Apr 2019 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)